Covid 19 vaccine update: Those that work – and the others on the way

Covid 19 vaccine update:

It is more than a year since the virus first emerged, yet the vast majority of people are still vulnerable.

The restrictions on our lives are the only thing holding the virus in check as they reduce opportunities for the virus to spread.

Vaccines teach our bodies to fight the infection and are “the” exit strategy from the pandemic.

The three vaccine frontrunners are those developed by Pfizer/BioNTech, Moderna and Oxford/AstraZeneca.

Pfizer and Moderna have both developed RNA vaccines – a new approach that is incredibly quick to design.

They inject a tiny fragment of the virus’s genetic code into the body, which starts producing part of the

coronavirus and pushes the body to mount a defence.

These have been approved for use in the UK, Europe and the US.

The Oxford vaccine is subtly different as it uses a harmless virus to carry the same genetic material into the body.

This has been approved in the UK and Europe.

It is the easiest of the three to use as it can be stored in a fridge, rather than needing very cold temperatures.

All three are supposed to be given as two doses, but the UK is prioritising giving as many people as possible the

first dose and delaying the second.

Results from large-scale trials on two new vaccines have also been presented recently.

The work by Janssen, which is owned by Johnson & Johnson, and Novavax will now be reviewed by drugs

regulators before their jabs can be approved.

Janssen’s vaccine uses the same technique as Oxford, but crucially is given as a single injection, rather than two.

This, combined with it needing only a fridge to store and a billion doses planned this year, means it could make a

significant impact around the world.

Novavax is using a different, old-school, approach to vaccines – proteins from the virus and a chemical to prime

the immune system are injected into the body.

There are other noteworthy vaccines, even if they are not being used in Europe and the US.

The Sinovac, CanSino and Sinopharm vaccines have been developed by scientists in China and deals have signed

with other countries in Asia and South America. Around one million people in China are reported to have been

given the Sinopharm injection.

The Sputnik V vaccine, developed by Russia’s Gamaleya Research Centre, is also effective according to late stage trial results published in The Lancet.

Some people have been immunised.

The vaccine, which works in a similar way to the Oxford/AstraZeneca and Janssen vaccines has also been deemed

to be safe – and offer complete protection against hospitalisation and death.

It is hard to compare one company’s results with another as their trials will have been conducted in slightly

different ways and at different points in the pandemic.

However, all the main vaccines seem to have a large impact on your chances of needing hospital treatment or dying from Covid.

Nonetheless, one of the most important questions – do they stop you spreading the virus – remains unknown.

Understanding which method produces the best results will be explored in challenge trials where people are

deliberately infected with the virus.

New versions of the coronavirus are emerging in countries around the world.

However, there is a warning sign from Janssen and Novavax, which have the first “real-world” data on the new variants.

Both showed a dip in their overall effectiveness in South Africa, where a new and worrying variant has been spreading.

The results were still good and clearly better than no vaccine at all, but they emphasise how coronavirus is a

moving target.

We may need to change the vaccines we use in the future.